Sumitomo Pharma Co., Ltd. (DNPUF)
| Market Cap | 4.93B +242.4% |
| Revenue (ttm) | 2.85B +13.7% |
| Net Income | 672.09M +352.2% |
| EPS | 1.69 +352.2% |
| Shares Out | n/a |
| PE Ratio | 7.33 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 500 |
| Average Volume | 184 |
| Open | 10.70 |
| Previous Close | n/a |
| Day's Range | 10.70 - 10.70 |
| 52-Week Range | 6.34 - 19.20 |
| Beta | 0.48 |
| RSI | 35.57 |
| Earnings Date | May 13, 2026 |
About Sumitomo Pharma
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson’s disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, antiepileptic, atypical antipsychotic, and carbapenem antibiotic. In addition, it offers veterinary medicines, medical devices, etc. The company has coll... [Read more]
Financial Performance
In fiscal year 2026, Sumitomo Pharma's revenue was 453.29 billion, an increase of 13.66% compared to the previous year's 398.83 billion. Earnings were 106.87 billion, an increase of 352.17%.
Financial numbers in JPY Financial StatementsNews
Sumitomo Pharma shares plunge 12% despite greenlight for Parkinson's treatment
Shares of Japan's Sumitomo Pharma fell over 12%. Japanese government endorsed the company's iPS cell-based therapy for Parkinson's and heart disease.
Sumitomo Pharma Earnings Call Transcript: Q3 2026
Q3 FY2025 saw strong revenue and profit growth, driven by North American product sales and cost controls. Full-year guidance is unchanged due to expected Q4 seasonality, while oncology R&D and partnering timelines have shifted to maximize asset value.
Sumitomo Pharma Earnings Call Transcript: Q2 2026
Q2 FY2025 saw revenue and profit surge above forecasts, driven by strong North America sales, a JPY 49 billion gain from the China-Asia business transfer, and disciplined cost control. Full-year guidance was raised, with Orgovyx expected to surpass $1 billion in sales.
Sumitomo Pharma upgraded to Equal Weight from Underweight at Morgan Stanley
Morgan Stanley upgraded Sumitomo Pharma (DNPUF) to Equal Weight from Underweight with a price target of 1,350 yen, up from 550 yen. Orgovyx sales are “on a roll” with U.S.
Sumitomo Pharma Earnings Call Transcript: Q1 2026
Q1 FY2025 saw strong revenue and profit growth, led by North America, with ORGOVYX and GEMTESA outperforming plans. Full-year guidance is unchanged due to uncertainties, but significant one-time gains are expected in H1. R&D and governance initiatives continue to advance.
Sumitomo Pharma Earnings Call Transcript: Q4 2025
FY 2024 saw a strong recovery with revenue up 27% year-over-year, driven by U.S. product growth and major cost reductions. FY 2025 guidance anticipates lower revenue due to business transfers and loss of exclusivity, but higher core operating profit and continued focus on key products.
Sumitomo Pharma Earnings Call Transcript: Q3 2025
Returned to profitability with strong revenue growth and cost reductions, raising full-year forecasts. North American products outperformed, while Japan faced headwinds from loss of exclusivity. Ongoing refinancing and R&D prioritization continue.
Sumitomo Pharma upgraded to Neutral from Sell at Citi
Citi analyst Hidemaru Yamaguchi upgraded Sumitomo Pharma to Neutral from Sell with a price target of 460 yen, up from 190 yen. The firm says Orgovyx is strong in the
Sumitomo Pharma, Poxel announce topline results from TWINKLE study
Sumitomo Pharma and Poxel announced topline results obtained from a post-marketing clinical study, TWINKLE, in Japanese type 2 diabetic patients with renal impairment for Twymeeg Tablets 500 mg being ...